Details for Patent: 8,058,291
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
Which drugs does patent 8,058,291 protect, and when does it expire?
Patent 8,058,291 protects NAMZARIC and is included in one NDA.
This patent has fifty-seven patent family members in eighteen countries.
Summary for Patent: 8,058,291
| Title: | Methods and compositions for the treatment of CNS-related conditions |
| Abstract: | The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease. |
| Inventor(s): | Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA) |
| Assignee: | Adamas Pharmaceuticals, Inc. (Emeryville, CA) |
| Application Number: | 11/399,879 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,058,291 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; Composition; Formulation; |
Drugs Protected by US Patent 8,058,291
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-003 | Jul 18, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Sign Up | ||||
| Allergan | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-001 | Dec 23, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Sign Up | ||||
| Allergan | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-004 | Jul 18, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Sign Up | ||||
| Allergan | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-002 | Dec 23, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,058,291
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 481096 | ⤷ Sign Up | |||
| Australia | 2005209310 | ⤷ Sign Up | |||
| Australia | 2005215767 | ⤷ Sign Up | |||
| Australia | 2005215775 | ⤷ Sign Up | |||
| Australia | 2005309601 | ⤷ Sign Up | |||
| Australia | 2006244297 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
